| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: ACHN |
| Security Type |
Common Stock |
| Lead Underwriter |
SG Cowen Securities Corp |
| Days In Registration |
208 |
| Date Filed |
31-Mar-2006 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Achillion Pharmaceuticals Inc, located in New Haven, Connecticut, develops and manufactures treatment for infectious diseases mainly antivirals and antibacterials. Its product pipeline includes elvucitabine, ACH-702, and multiple NS4A antagonists. The company was incorporated in Delaware in August 1998. |
| Revenue |
$3.3M |
| Net Income |
-$24.1M |
| Shares Outstanding (post-offering) |
14.85M |
| Contact |
- |
| Number of Employees |
63 |
|
| Original Filing Information |
| US |
| Shares Filed |
4.5M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
4.5M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
675.0K |
| File Amount |
$67.5M |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
Current Filing Information
(Amended 25-Oct-2006) |
|
US |
|
Shares Filed |
4.5M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.5M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$67.5M |
| · % Change from Original |
0.0 |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
|
